Logo image of ALZN

ALZAMEND NEURO INC (ALZN) Stock Fundamental Analysis

USA - NASDAQ:ALZN - US02262M6057 - Common Stock

2.62 USD
+0.27 (+11.49%)
Last: 9/16/2025, 8:00:00 PM
2.63 USD
+0.01 (+0.38%)
After Hours: 9/16/2025, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, ALZN scores 2 out of 10 in our fundamental rating. ALZN was compared to 540 industry peers in the Biotechnology industry. While ALZN seems to be doing ok healthwise, there are quite some concerns on its profitability. ALZN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALZN had negative earnings in the past year.
In the past year ALZN has reported a negative cash flow from operations.
ALZN had negative earnings in each of the past 5 years.
ALZN had a negative operating cash flow in each of the past 5 years.
ALZN Yearly Net Income VS EBIT VS OCF VS FCFALZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

ALZN has a worse Return On Assets (-112.07%) than 78.33% of its industry peers.
With a Return On Equity value of -130.00%, ALZN is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -112.07%
ROE -130%
ROIC N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALZN Yearly ROA, ROE, ROICALZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALZN Yearly Profit, Operating, Gross MarginsALZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ALZN has been increased compared to 1 year ago.
Compared to 5 years ago, ALZN has more shares outstanding
ALZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALZN Yearly Shares OutstandingALZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
ALZN Yearly Total Debt VS Total AssetsALZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 5M 10M

2.2 Solvency

ALZN has an Altman-Z score of -13.13. This is a bad value and indicates that ALZN is not financially healthy and even has some risk of bankruptcy.
ALZN has a Altman-Z score of -13.13. This is in the lower half of the industry: ALZN underperforms 77.78% of its industry peers.
There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.13
ROIC/WACCN/A
WACCN/A
ALZN Yearly LT Debt VS Equity VS FCFALZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 6.58 indicates that ALZN has no problem at all paying its short term obligations.
ALZN has a better Current ratio (6.58) than 66.11% of its industry peers.
A Quick Ratio of 6.58 indicates that ALZN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.58, ALZN is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.58
Quick Ratio 6.58
ALZN Yearly Current Assets VS Current LiabilitesALZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

1

3. Growth

3.1 Past

ALZN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.44%.
EPS 1Y (TTM)-22.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.79% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.04%
EPS Next 2Y40.71%
EPS Next 3Y25.55%
EPS Next 5Y14.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALZN Yearly Revenue VS EstimatesALZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M
ALZN Yearly EPS VS EstimatesALZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALZN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALZN Price Earnings VS Forward Price EarningsALZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALZN Per share dataALZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as ALZN's earnings are expected to grow with 25.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.71%
EPS Next 3Y25.55%

More info and screens

0

5. Dividend

5.1 Amount

ALZN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALZAMEND NEURO INC

NASDAQ:ALZN (9/16/2025, 8:00:00 PM)

After market: 2.63 +0.01 (+0.38%)

2.62

+0.27 (+11.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-10 2025-09-10/amc
Earnings (Next)N/A N/A
Inst Owners0.21%
Inst Owner Change-72.03%
Ins Owners0.88%
Ins Owner Change8.14%
Market Cap8.23M
Analysts80
Price Target45.9 (1651.91%)
Short Float %4.41%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-75%
PT rev (3m)-75%
EPS NQ rev (1m)81.3%
EPS NQ rev (3m)81.3%
EPS NY rev (1m)55.51%
EPS NY rev (3m)55.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-247.95
EYN/A
EPS(NY)-4.98
Fwd EYN/A
FCF(TTM)-2.19
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS0
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.07%
ROE -130%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 591.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.58
Quick Ratio 6.58
Altman-Z -13.13
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)294.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.62%
EPS Next Y94.04%
EPS Next 2Y40.71%
EPS Next 3Y25.55%
EPS Next 5Y14.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.58%
OCF growth 3YN/A
OCF growth 5YN/A